BELPHARMED

The computed 12-month bankruptcy probability of BELPHARMED is 2.4% (moderate). The 2025 annual accounts show equity of €15,741 and a net result of €876. Equity is growing by about 5.2% per year across the filed financial years. Its solvency ranks better than 9% of 6,081 sector peers (NACE 46, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals.